Implantable sandwich PHBHHx film for burst-free controlled delivery of thymopentin peptide.
10.1016/j.apsb.2018.03.003
- Author:
Ke PENG
1
;
Chengyu WU
1
;
Guoxu WEI
1
;
Jinghui JIANG
1
;
Zhirong ZHANG
1
;
Xun SUN
1
Author Information
1. Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- Keywords:
Burst-free release;
Immune enhancement;
PHBHHx;
Sustained release;
Thymopentin
- From:
Acta Pharmaceutica Sinica B
2018;8(3):432-439
- CountryChina
- Language:English
-
Abstract:
Sustained release and non-parental formulations of peptides and protein drugs are highly desirable because of enhanced therapeutic effects as well as improved patient compliance. This is especially true for small peptides such as thymopentin (TP5). To this end, implantable sandwich poly (hydroxybutyrate--hydroxyhexanoate) (PHBHHx) films were designed to prolong release time and to inhibit burst release phenomenon of TP5 by a simple volatilization method. release studies revealed that sandwich films had nearly no burst release. release time of sandwich films was prolonged to 42 days. Pharmacodynamic evaluation demonstrated that TP5 sandwich films significantly increased survival rates in a rat immunosuppressive model and normalized CD4/CD8 values. These results suggest that TP5 released from sandwich films can attenuate cyclophosphamide's immunosuppressive activity, and possibly achieve results comparable to daily TP5 injection therapy. Thus, sandwich PHBHHx films show excellent potential as a sustained, burst-free release system for small molecular weight, hydrophilic peptide drugs.
